SARFATI ET AL.
BRIEF DEFINITIVE REPORT and cycloheximide (CHX) (Sigma Chemical Co.) was used at 100,ug/ml . After a 12-d culture, cell viability was -95%, except in the cultures supplemented with CHX .
Immunofluorescence. Fresh CLL cells were stained for surface Ig L chain (SIg') and CD5 and CD23 antigen expression using FITC-F(ab)2 goat anti-human is or X (Tago Inc., Burlingame, CA), at a dilution of 1 :100, and phycoerythrin-conjugated anti-CD5 (Becton Dickinson & Co., Mountain View, CA), and biotinylated anti-CD23, followed by FITC-avidine at a dilution of 1 :50, respectively. The proportion of stained cells (percent) was measured by flow cytometry (FACScan; Becton Dickinson & Co.). For the detection of intracytoplasmic IgE (IC* IgE), PBMC from the same CLL patients were cultured in the presence of a mixture of IL-4 (400 U/ml) and HC (10 -5 M) . After 12 d, the cells were washed, cytocentrifuged onto microscope slides, fixed in ice-cold methanol, and stained with anti-IgE mAb (clone 4.15) (a gift from Dr. Saxon, UCLA) at 5 lAg/ml, followed by FITC-F(ab')2 goat anti-mouse Ig (Tago Inc.) at the dilution of 1 :40 . Fluorescent cells were quantified using a fluorescence microscope (E. Leitz, Inc., Rockleigh, NJ) (apochrome; 63 x objective).
RIAs. Total IgE, in the various culture supernatants (CSN), was measured by RIA exactly as previously described (15) . Two anti-IgE mAbs were used in this assay. Clone 89 (10 pg/ml), produced in our laboratory, was used to coat the wells of microtitre plate and clone 4.15, as '25 1-labeled mAb. The sensitivity of the assay was of 0.2 ng/ml. Specific IgE X and K were also measured by RIA. For this assay, the plates were coated with anti-IgE mAb (clone 89). After blocking, the CSN were allowed to incubate for 16 h. After washing, wells were incubated overnight with 125 1-radiolabeled F(ab')2 goat anti-human K or k (Tago Inc.), washed, and counted. IgE X (present in the CSN of the U266 IgE myeloma cell line) and IgE is (isolated from the serum of the IgE myeloma patient ADZ and kindly given by Dr. A. L. de Weck, Switzerland) were used as standards and as specificity controls for the respective assay. (Table I ). The level of IgE production ranges from 1.3 to 54 ng/ml and does not correlate with the number of circulating lymphocytes . The other classes of Ig are not induced in the same cultures (data not shown). It is important to note that CLL cells do not produce IgE in response to either IL-4 (up to 10,000 U/ml) or HC used alone. The concentrations of IL-4 (400 U/ml) and of HC (10-5 M) used in these experiments have been selected in preliminary dose-response studies . The four nonresponder patients have been tested twice with negative results, whereas all responders have been tested three consecutive times at a 1-mo interval with positive results. Neither clinical stage nor lymphocyte count can differentiate IgE responders from nonresponders . Moreover, the two groups of patients display similar immunological parameters, i.e., same K/X distribution, similar range ofCD5 expression (80-95% positive cells), and CD23 expression (60-85% positive cells) . In contrast, normal PBMC synthesize IgE upon stimulation with IL-4 alone and this response is enhanced by HC (Table II) . The following observations indicate that the IgE detected in the CSN of CLL cells is not preformed or of extrinsic origin : (a) IgE cannot be detected in the CSN of either unstimulated cells or of cells costimulated with IL-4 and HC and supplemented with cycloheximide, a protein synthesis inhibitor (Table I) ; and (b) the IL-4-and HC-stimulated cultures contain cells with intracytoplasmic IgE (Ic' IgE) (Table III) . CLL Lymphocytes SynthesizeMonoclonal IgE. As indicated in Table III , the costimulation with IL-4 and HC induces the tumor cell population and most likely not the contaminating normal B cells to synthesize IgE. Indeed, all the secreted IgE molecules Freshly isolated PBMC from CLL patients were stained for surface Ig L chain expression (sIg') using FITC-F(ab')2 goat anti-human is or X . Stained cells were counted using a FACS analyser (Becton Dickinson & Co .) . PBMC from the same CLL patients were also cultured in the presence of IL-4 (400 U/ml) and/or HC (10-5 M), as indicated in Materials and Methods . After a 12-d culture, CSN were collected and IgE was measured by RIA, as described in Materials and Methods. The data are the mean values of eight replicate cultures . The coefficient of variation was <20% . No IgE was detected in IL-4-and HC-stimulated cultures in the presence of CHX (100 ug/ml) .
Results

CLL
express the same L chain type as the freshly isolated monoclonal CD5+ B-CLL cells. The RIAs for the detection of IgE tc and IgE X are highly specific. Up to 250 ng/ml of IgE A gives background cpm levels ( t 500 cpm; total count, 2 x 105 cpm) when reacted with 125 1-anti-u antibody, and similarly, IgE u does not bind to 125 1-anti-A antibody. Moreover, the IL-4-induced IgE produced by normal PBMC is made of a mixture of IgE rc and IgE X (data not shown) . Discussion This study indicates that B-CLL cells are capable of differentiating into monoclonal IgE-producing cells and that, in contrast to normal PBMC, both IL-4 and HC are required to trigger IgE synthesis. The mechanisms underlying the apparent permissive effect of glucocorticosteroids (GCS) on the response of B-CLLs to IL-4, as well as their enhancing activity of the IL-4-induced IgE synthesis by normal lymphocytes, are currently investigated . The influence ofGCS on human IgE synthesis is not well documented, and contradictory reports have been published (16, 17) . However, physiological concentrations of GCS were reported to induce Ig production (IgG, IgA, and IgM) by purified normal B cells in the presence of monocytes and T-replacing factor for steroids (TRF S). TRFS is a 40-kD protein produced by CD4+ T cells upon incubation with GCS and IL-1 (18) . GCS can also induce the differentiation of B-CLLs into IgM-producing cells after activation with Staphylococcus aureus Cowan 1 and IL-2, in the absence of T cells but in the presence ofmonocytes. The latter may be replaced by IL-1 and IL-6 (19) . These data suggest that GCS act by modulating monocyte-B cell interactions . A similar mechanism might account for their potentiating or "permissive" effect on IgE synthesis by normal PBMC and B-CLLs, respectively. Indeed, it was recently shown that the IL-4-induced synthesis by normal PBMC is IL-6 dependent (20) , and that B-CLL cells constitutively produce .
Since the patients included in this study have been tested more than once with the same results, they may be grouped into IgE responders and nonresponders. The two groups do not differ by clinical or hematological parameters . For example, PBMC from all the CLL patients contain >80% CD5+ B cells and from 60 to 85% CD23 + B cells, Moreover, none of the patients have received prior chemotherapy, including GCS. It is therefore anticipated that analysis of the phenotypic and functional characteristics of the B-CLLs from these two groups of patients will generate basic information regarding IgE precursor B cells and/or the cellular interactions leading to their differentiation into IgE-secreting cells. As such, the present study may be viewed Summary The present results indicate that B cells isolated from chronic lymphocytic leukemia (B-CLL) from 11 of 14 patients are capable ofspecifically producing IgE upon costimulation with IL-4 and hydrocortisone (HC). IgE is detected by intracytoplasmic fluorescence staining and by RIA . Clinical, hematological, and immunological parameters (including Rai stage, WBC, Lc, SIg K/X, CD5, and CD23 expression) cannot distinguish the IgE responder from the nonresponder patients. IL-4 alone is a potent inducer of human IgE synthesis by normal PBMC and we show here that its effect is strikingly enhanced by HC. The IgE produced by B-CLLs are monoclonal since they display the same L chain type as the freshly isolated CD5 + B-CLLs . We, therefore, conclude that the combination of IL-4 and HC can abrogate the maturation arrest of CD5 + B-CLLs by inducing their differentiation into IgE-producing cells. The present data provide a unique model to study the isotype switching to IgE and the regulation of human IgE synthesis by monoclonal human B cells.
